Franklin Ellenson, MD
Neurology · Anchorage, AKNPI 1780622423
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.4% of the total across 107 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 12.8% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for neurology clinicians in AK, where the typical reported total is $2,594.
Across 107 payments — averaging $21.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- EMD Serono, Inc.$293
- AbbVie$230
- Eisai Inc.$219
- Lundbeck LLC$216
- Pfizer$160
- Genentech USA, Inc.$146
- plus $1K from 24 others
What the payments were for
- Food & beverage$2,25798%
- Education$362%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| EMD Serono, Inc. | 11 | $293 |
| AbbVie(2 entities) | 11 | $230 |
| Eisai Inc. | 7 | $219 |
| Lundbeck LLC | 12 | $216 |
| Pfizer | 9 | $160 |
| Genentech USA, Inc. | 9 | $146 |
| TG Therapeutics, Inc. | 4 | $130 |
| Teva Pharmaceuticals USA, Inc. | 6 | $124 |
| Argenx US, Inc. | 4 | $119 |
| Sunovion Pharmaceuticals Inc. | 6 | $104 |
| Biogen | 3 | $65 |
| UCB, Inc. | 3 | $60 |
| Acadia Pharmaceuticals Inc | 3 | $53 |
| GE HealthCare | 2 | $35 |
| Jazz Pharmaceuticals Inc. | 2 | $33 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $31 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $30 |
| Catalyst Pharmaceuticals, Inc. | 1 | $27 |
| TMS Neurohealth Centers Inc. | 1 | $25 |
| Vanda Pharmaceuticals Inc. | 1 | $25 |
| Sarepta Therapeutics, Inc. | 1 | $23 |
| CSL Behring | 1 | $21 |
| Nevro Corp. | 1 | $21 |
| Neurelis, Inc. | 1 | $20 |
| Alnylam Pharmaceuticals Inc. | 1 | $17 |
| AstraZeneca | 1 | $16 |
| Amgen | 1 | $14 |
| Inspire Medical Systems, Inc. | 1 | $13 |
| Amneal Pharmaceuticals LLC | 1 | $11 |
| Upsher-smith Laboratories LLC | 1 | $11 |
How this compares
$2,293 in reported general payments places this provider in the 40th percentile of 21 neurology providers in Alaska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UbrelvyUbrogepant | 33 | $32,998 |
| Aimovig AutoinjectorErenumab-Aooe | 39 | $29,675 |
| QuliptaAtogepant | 13 | $18,470 |
| Dalfampridine ErDalfampridine | 27 | $13,376 |
| AptiomEslicarbazepine Acetate | 11 | $12,842 |
| Rasagiline Mesylate | 16 | $8,991 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 98 | $6,085 |
| Carbamazepine ErCarbamazepine | 24 | $5,858 |
| BelsomraSuvorexant | 11 | $5,003 |
| Levetiracetam | 143 | $4,980 |
| Oxcarbazepine | 38 | $4,919 |
| Propranolol Hcl ErPropranolol Hcl | 76 | $3,985 |
| Memantine Hcl ErMemantine Hcl | 61 | $3,900 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 41 | $3,787 |
| Levetiracetam ErLevetiracetam | 18 | $3,199 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Qulipta | $230 | $51,46946 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $104 | $12,84211 claims |
| Upsher-smith Laboratories LLCTopiramate | $11 | $1,57292 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 21 neurology providers in Alaska.
Other neurology in Anchorage
- Stanford DownsAnchorage$19K
- Mary DownsAnchorage$17K
- Scot HinesAnchorage$8K
- David HenzlerAnchorage$6K
- Aaron TauerAnchorage$3K
- Thomas KennedyAnchorage$1K
- Marci TroxellAnchorage$593
- Robert LadaAnchorage$275
- Kim MaddenAnchorage$15
- Lawrence JedlickaAnchorage$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.